
Women in Medical Research: Breaking the Cycle of Exclusion
When it comes to medical research, one surprising reality is how often women have been left out.
For decades, women—especially those who could get pregnant—have been largely excluded from clinical trials. This has resulted in a healthcare system largely designed around male physiology. This gender bias isn’t just a historical footnote—it continues today, with serious consequences for women’s health.
A Long History of Exclusion
Back in the 1970s, the FDA recommended excluding women from early drug trials to protect potential pregnancies. While well-intentioned, this created a huge gap in understanding how treatments affect women differently.
Because most studies were done on men, doctors often assume men’s results apply to everyone. But women frequently experience different reactions to medications. For example, drug dosages are often based on male physiology, which can lead to higher risks of side effects for women. Heart disease symptoms also vary between men and women, yet women’s signs have historically been underrecognized, causing misdiagnosis and mistreatment.
Why Are Women Still Left Out?
Though progress has been made, women remain underrepresented in many clinical trials. Reasons include:
-
Research focus on male-dominant diseases
-
Trial criteria excluding pregnant women or those with certain health conditions
-
Lack of awareness among women about clinical trials
-
Concerns about time commitment and potential risks
-
Distrust due to past dismissal of women’s health concerns
The Price of Overlooking Women
This exclusion has profound effects. Treatments may be less effective or even harmful for women. For instance, heart disease—women’s leading cause of death—was long misunderstood as a “man’s disease,” delaying tailored treatments. Symptoms in women often differ, yet these were ignored due to lack of representation in studies.
Medication side effects can also vary due to differences in metabolism and hormones. Without adequate female participants, these risks remain hidden until after drugs reach the market.
A tragic example is thalidomide in the 1960s, a sedative that caused severe birth defects. Early trials excluded women, and the risks were only discovered after widespread harm.
Toward More Inclusive Research
Ignoring women in research means continuing to offer treatments not suited to their needs, leading to poorer health outcomes and stalled progress in understanding women’s health.
Solutions include:
-
Ensuring women are included in all research stages
-
Analyzing how treatments affect sexes differently
-
Promoting studies on women’s health issues (menopause, autoimmune diseases, reproductive health)
Recent advances, such as NIH policies for inclusion and new digital health tools enabling remote trial participation, are helping close the gap.
What Can We Do?
Awareness is the first step. Women should learn about research biases and be encouraged to participate in trials. Researchers and healthcare providers must commit to inclusive studies that prioritize women’s health.
By doing so, we can build a healthcare system that truly serves everyone—recognizing and respecting women’s unique health needs.
If you or someone you know is looking to understand their legal rights or seek support, please reach out to our app’s ‘Support’ and ‘Engage’ verticals for affordable and inclusive help.
This post represents the author’s personal views and experiences. iDare doesn’t endorse or take responsibility for the opinions expressed.
Like our content? Please show your support by sharing and up-voting!
Image Credits: Pexels.com